🇺🇸 FDA
Patent

US 11318186

Use of FGF21 in methods of increasing exocrine pancreatic secretion

granted A61KA61K38/1825A61K9/0019

Quick answer

US patent 11318186 (Use of FGF21 in methods of increasing exocrine pancreatic secretion) held by The Board of Regents of the University of Texas System expires Mon Apr 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue May 03 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K38/1825, A61K9/0019, A61K9/0053, A61P